Trial Profile

A Phase 1/2 Trial Evaluating the Combination of Temozolomide and the Ataxia Telangiectasia and Rad3-related Inhibitor M1774

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 11 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Temozolomide (Primary) ; Tuvusertib (Primary)
Indications Colorectal cancer; Malignant melanoma; Neuroendocrine tumours; Sarcoma; Small cell lung cancer; Solid tumours
Focus Adverse reactions

Most Recent Events

05 Mar 2025 Planned End Date changed from 31 Jan 2025 to 1 Mar 2027.
05 Mar 2025 Planned primary completion date changed from 31 Jan 2025 to 1 Mar 2027.
06 Sep 2023 Planned initiation date changed from 7 Sep 2023 to 6 Dec 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com